A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

This is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable esophageal squamous carcinoma.

Trial Details

NCT ID
NCT06869226
Phase
PHASE2
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Camrelizumab + Nab-paclitaxel + Cisplatin
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects voluntarily enrolled in this study, signed the informed consent form, had good compliance, and could cooperate with follow-up visits;
  • esophageal cancer diagnosed by histopathology; clinical staging of cT1b-cT2 N+ M0 or cT3, any N, M0 (according to AJCC 8th edition);
  • Age 18-75 years old, male or female;
  • ECOG PS 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →